ArticleHaematologica2025

Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies.

Pierre Peterlin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.